← All trials
NCT04943900
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Nov 13, 2023
- Completion date
- Nov 14, 2023
- First posted
- Jun 29, 2021
- Last posted
- Jun 29, 2021
- Enrollment
- 134
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.